Physician profile
Omer Basar
NPI 1801458617
$1,429.57
in general payments reported to CMS, 2019-2025
10 companies · $338 in 2025
The $338 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2021: $79.08 · 2022: $258 · 2023: $434 · 2024: $105 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $877.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $463.28 | 2022-2025 | Viberzi, Linzess |
| Boston Scientific Corporation | $336.64 | 2023-2025 | Exalt Model D, Orcapod, Resolution 360 Clip |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $162.25 | 2019-2025 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $124.72 | 2019 | |
| Genzyme Corporation | $98.61 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $82.97 | 2022 | |
| Janssen Scientific Affairs, LLC | $79.08 | 2021 | |
| Madrigal Pharmaceuticals | $38.70 | 2025 | Rezdiffra |
| Celltrion USA INC. | $24.95 | 2024 | Vegzelma |
| Aimmune Therapeutics, INC. | $18.37 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omer Basar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.